Golden
Owlstone Medical

Owlstone Medical

Owlstone Medical is a diagnostic medical device company developing non-invasive diagnostics such as breathalyzers for cancer, inflammatory disease and infectious disease.

Owlstone Medical develops non-invasive diagnostics for cancer, inflammatory disease and infectious disease. The company developed a breathalyzer for disease detection. Their Breath Biopsy platform is used to discover novel non-invasive biomarkers in breath which could transition to point-of-care. The ReCIVA Breath Sampler collects breath samples and analyzes volatile organic compounds (VOCs) using the microchip chemical senor technology, FAIMS (High Field Asymmetric waveform Ion Mobility Spectrometry), which detects biomarkers of disease.

Owlstone is developing tests for lung cancer, colorectal cancer and asthma stratification by therapeutic response. The company also offers Breath Biopsy products and services to academic, clinical and pharma partners looking to develop breath based diagnostics for their own applications.

Timeline

November 8, 2019

Thermo Fisher, Owlstone Medical collaborate for cancer diagnosis

2004

Owlstone Medical was founded.

Funding rounds

Funding round
Description
Funding round amount (USD)
Funding type
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Billy Boyle

Co-Founder, CEO

David Ruiz-Alonso

Co-Founder, COO

Martin Cartwright

CFO

Max Allsworth

CSO

Further reading

Title
Author
Link
Type
Date
+ Add new row

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services
+ Add new row

References